InterVenn unlocks the glycoproteome using artificial intelligence for the development of transformational healthcare solutions in DX and Rx.
InterVenn has raised $201.0M in total funding. The most recent round was Series C. The last funding was announced in August 2021.
InterVenn's investors include Amplify Partners, True Ventures, SoftBank Group, Anzu Partners, Genoa Ventures.
InterVenn is headquartered in South San Francisco, United States.
InterVenn unlocks the glycoproteome using artificial intelligence for the development of transformational healthcare solutions in DX and Rx.
InterVenn is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"InterVenn — Funding & Investors." VCBacked, August 2, 2021, https://www.vcbacked.co/company/intervenn. Accessed August 13, 2026.
VCBacked. (2021). InterVenn — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/intervenn
{{cite web |title=InterVenn — Funding & Investors |url=https://www.vcbacked.co/company/intervenn |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated